Search Results - "Stroyakovskiy, Daniil"

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma by Robert, Caroline, Grob, Jean J, Stroyakovskiy, Daniil, Karaszewska, Boguslawa, Hauschild, Axel, Levchenko, Evgeny, Chiarion Sileni, Vanna, Schachter, Jacob, Garbe, Claus, Bondarenko, Igor, Gogas, Helen, Mandalá, Mario, Haanen, John B.A.G, Lebbé, Celeste, Mackiewicz, Andrzej, Rutkowski, Piotr, Nathan, Paul D, Ribas, Antoni, Davies, Michael A, Flaherty, Keith T, Burgess, Paul, Tan, Monique, Gasal, Eduard, Voi, Maurizio, Schadendorf, Dirk, Long, Georgina V

“…In long-term follow-up of more than 500 patients with melanoma containing a BRAF V600E or V600K mutation, a combination of dabrafenib plus trametinib was…”
Get full text

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma by Larkin, James, Ascierto, Paolo A, Dréno, Brigitte, Atkinson, Victoria, Liszkay, Gabriella, Maio, Michele, Mandalà, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Dutriaux, Caroline, Garbe, Claus, Sovak, Mika A, Chang, Ilsung, Choong, Nicholas, Hack, Stephen P, McArthur, Grant A, Ribas, Antoni

“…The combination of inhibitors to BRAF and MEK improved response rates and progression-free survival among patients with metastatic melanoma. Some toxicity was…”
Get full text

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study by Hurvitz, Sara A, Martin, Miguel, Jung, Kyung Hae, Huang, Chiun-Sheng, Harbeck, Nadia, Valero, Vicente, Stroyakovskiy, Daniil, Wildiers, Hans, Campone, Mario, Boileau, Jean-François, Fasching, Peter A, Afenjar, Karen, Spera, Gonzalo, Lopez-Valverde, Vanesa, Song, Chunyan, Trask, Peter, Boulet, Thomas, Sparano, Joseph A, Symmans, W Fraser, Thompson, Alastair M, Slamon, Dennis

“…The KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, trastuzumab plus P (TCH+P) for the…”
Get full text

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial by Grob, Jean Jacques, Prof, Amonkar, Mayur M, PhD, Karaszewska, Boguslawa, MD, Schachter, Jacob, Prof, Dummer, Reinhard, Prof, Mackiewicz, Andrzej, Prof, Stroyakovskiy, Daniil, MD, Drucis, Kamil, MD, Grange, Florent, MD, Chiarion-Sileni, Vanna, MD, Rutkowski, Piotr, Prof, Lichinitser, Mikhail, Prof, Levchenko, Evgeny, MD, Wolter, Pascal, MD, Hauschild, Axel, Prof, Long, Georgina V, MD, Nathan, Paul, MD, Ribas, Antoni, Prof, Flaherty, Keith, MD, Sun, Peng, PhD, Legos, Jeffrey J, PhD, McDowell, Diane Opatt, MD, Mookerjee, Bijoyesh, MD, Schadendorf, Dirk, Prof, Robert, Caroline, MD

“…Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were…”
Get full text

Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab by Stroyakovskiy, Daniil L, Fadeeva, Natalya V, Matrosova, Marina P, Shelepen, Konstantin G, Adamchuk, Grigoriy A, Roy, Bodhisatta, Nagarkar, Rajnish, Kalloli, Mahesh, Zhuravleva, Daria, Voevodin, Georgiy D, Shustova, Mariya S, Kryukov, Fedor

“…BCD-021 is a bevacizumab biosimilar which was shown to be equivalent to reference bevacizumab in a wide panel of physicochemical studies as well as preclinical…”
Get full text

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer by Slamon, Dennis J., Fasching, Peter A., Hurvitz, Sara, Chia, Stephen, Crown, John, Martín, Miguel, Barrios, Carlos H., Bardia, Aditya, Im, Seock-Ah, Yardley, Denise A., Untch, Michael, Huang, Chiun-Sheng, Stroyakovskiy, Daniil, Xu, Binghe, Moroose, Rebecca L., Loi, Sherene, Visco, Frances, Bee-Munteanu, Valerie, Afenjar, Karen, Fresco, Rodrigo, Taran, Tetiana, Chakravartty, Arunava, Zarate, Juan Pablo, Lteif, Agnes, Hortobagyi, Gabriel N.

“…Background: Ribociclib has demonstrated a statistically significant overall survival benefit in pre- and postmenopausal patients with hormone receptor…”
Get full text

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer by Prager, Gerald W., Taieb, Julien, Fakih, Marwan, Ciardiello, Fortunato, Van Cutsem, Eric, Elez, Elena, Cruz, Felipe M., Wyrwicz, Lucjan, Stroyakovskiy, Daniil, Pápai, Zsuzsanna, Poureau, Pierre-Guillaume, Liposits, Gabor, Cremolini, Chiara, Bondarenko, Igor, Modest, Dominik P., Benhadji, Karim A., Amellal, Nadia, Leger, Catherine, Vidot, Loïck, Tabernero, Josep

Get full text

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study by Tabernero, Josep, Prager, Gerald W., Fakih, Marwan, Ciardiello, Fortunato, Van Cutsem, Eric, Elez, Elena, Cruz, Felipe Melo, Wyrwicz, Lucjan, Stroyakovskiy, Daniil, Papai, Zsuzsanna, Poureau, Pierre-guillaume, Liposits, Gabor, Cremolini, Chiara, Bondarenko, Igor, Modest, Dominik Paul, Benhadji, Karim A., Fougeray, Ronan, Leger, Catherine, Amellal, Nadia, Taieb, Julien

“…4 Background: Trifluridine/tipiracil (FTD/TPI) plus bevacizumab (Bev) demonstrated promising efficacy in a randomized phase 2 trial of heavily pretreated…”
Get full text

Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE) by Orlova, Kristina V., Ledin, Evgeniy V., Zhukova, Natalia V., Orlova, Rashida V., Karabina, Elena V., Volkonskiy, Mikhail V., Stroyakovskiy, Daniil L., Yurchenkov, Aleksandr N., Protsenko, Svetlana A., Novik, Alexey V., Vorotilina, Ludmila V., Moiseenko, Fedor V., Chang, Victor L., Kazmin, Aleksandr I., Tkachenko, Svetlana A., Gamaunov, Sergey V., Naskhletashvili, David R., Samoylenko, Igor V., Vikhrova, Anastasia S., Utyashev, Igor A., Kharkevich, Galina Yu, Petenko, Natalia N., Shubina, Irina Zh, Demidov, Lev V.

“…Clinical trials of targeted therapy (TT) and immunotherapy (IT) for highly aggressive advanced melanoma have shown marked improvements in response and survival…”
Get full text

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC by Jotte, Robert M., Cappuzzo, Federico, Vynnychenko, Ihor, Stroyakovskiy, Daniil, Rodriguez Abreu, Delvys, Hussein, Maen A., Soo, Ross A., Conter, Henry Jacob, Kozuki, Toshiyuki, Silva, Carlos, Graupner, Vilma, Sun, Shawn, Lin, Ray S, Kelsch, Claudia, Kowanetz, Marcin, Hoang, Tien, Sandler, Alan, Socinski, Mark A.

“…Abstract only LBA9000 Background: Atezolizumab (atezo; anti–PD-L1) demonstrated OS benefit vs docetaxel in 2L+ NSCLC regardless of PD-L1 status or tumor…”
Get full text

Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC by Socinski, Mark A., Jotte, Robert M., Cappuzzo, Federico, Orlandi, Francisco Jorquera, Stroyakovskiy, Daniil, Nogami, Naoyuki, Rodriguez-Abreu, Delvys, Moro-Sibilot, Denis, Thomas, Christian A., Barlesi, Fabrice, Finley, Gene Grant, Kelsch, Claudia, Lee, Anthony, Coleman, Shelley, Shen, Yijing, Kowanetz, Marcin, Lopez-Chavez, Ariel, Sandler, Alan, Reck, Martin

“…Abstract only…”
Get full text

Cobimetinib combined with vemurafenib in advanced BRAFV600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial by Ascierto, Paolo A, MD, McArthur, Grant A, Prof, Dréno, Brigitte, Prof, Atkinson, Victoria, MD, Liszkay, Gabrielle, MD, Di Giacomo, Anna Maria, MD, Mandalà, Mario, MD, Demidov, Lev, MD, Stroyakovskiy, Daniil, MD, Thomas, Luc, Prof, de la Cruz-Merino, Luis, MD, Dutriaux, Caroline, MD, Garbe, Claus, Prof, Yan, Yibing, PhD, Wongchenko, Matthew, BS, Chang, Ilsung, PhD, Hsu, Jessie J, PhD, Koralek, Daniel O, PhD, Rooney, Isabelle, MBChB, Ribas, Antoni, Prof, Larkin, James, FRCP

“…Summary Background The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously…”
Get full text

301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study by Ascierto, Paolo, Lewis, Karl, Robert, Caroline, Stroyakovskiy, Daniil, Gogas, Helen, Protsenko, Svetlana, Pereira, Rodrigo, Eigentler, Thomas, Rutkowski, Piotr, Demidov, Lev, Manikhas, Georgy Moiseevich, Li, Haocheng, Zhu, Qian, McKenna, Edward, McNally, Virginia, Gutzmer, Ralf, McArthur, Grant

“…BackgroundThe phase 3 IMspire150 study (NCT02908672) demonstrated improved progression-free survival (PFS) with first-line atezolizumab (A) vs placebo (P)…”
Get full text

Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study by Zhukova, Liudmila G., Bolotina, Larisa V., Dvornichenko, Victoria V., Fadeeva, Natalia V., Ganshina, Inna P., Grechukhina, Katerina S., Hasanova, Alfiya I., Kislov, Nikolay V., Kudryavtsev, Igor Yu, Manikhas, Alexey G., Musaeva, Natalia E., Nizhegorodtseva, Alexandra A., Sadikova, Olga E., Sakaeva, Dina D., Snegovoy, Anton V., Stroyakovskiy, Daniil L., Tjulandin, Sergei A., Trishkina, Ekaterina A., Vladimirova, Liubov Iu, Volkov, Nikita M., Kostalanova, Yulia V.

“…Background. The use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in combination with endocrine therapy is a key initial treatment for advanced…”
Get full text

Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study by Samoylenko, Igor V., Demidov, Lev V., Moiseenko, Fedor V., Dvorkin, Mikhail V., Demidova, Svetlana A., Protsenko, Svetlana A., Stroyakovskiy, Daniil L., Kozlov, Vadim V., Odintsova, Svetlana V., Kirtbaya, Dmitry V., Tantsyrev, Denis A., Mochalova, Anastasia S., Orlova, Rashida V., Mukhametshina, Guzel Z., Fadeeva, Natalia V., Fomin, Evgeny A., Chapko, Yana S., Tarasova, Anna V., Ermakov, Nikolay B., Shemerovskiy, Alexander K., Vaschenko, Vera A., Chistyakov, Valery M., Zinkina-Orikhan, Arina V., Lin'kova, Yulia N., Kryukov, Fedor B., Sorokina, Irina V., Siliutina, Anna A.

“…Background. In an era of breakthroughs in cancer immunotherapy, CheckMate 067 studies declared the combination of PD-1 and CTLA-4 inhibitors a new standard of…”
Get full text

Multicenter prospective observational post-approval study of safety and efficacy of bevacizumab (Avegra®, BIOCAD) in patients with metastatic colorectal cancer in real world practice: APOLLON-11 and SOYUZ-APOLLON by Tryakin, Alexey A., Fedyanin, Mikhail Yu, Moiseenko, Fedor V., Mironov, Oleg V., Stroyakovskiy, Daniil L., Sokolov, Nikolai Iu, Orlova, Svetlana A., Mantsyrev, Evgenii O., Sultanbaev, Alexander V., Teterich, Antonina A., Babina, Kseniia G., Yukalchuk, Denis Yu, Borzyanitsa, Stanislav M., Isyangulova, Alina Z., Saidullaeva, Aleksandra F., Chernova, Yuliia A., Bobrova, Elvira A., Fadeeva, Natalia V., Chobanu, Dmitrii Yu

“…Aim. To evaluate the safety and efficacy of long-term continuous use of Avegra BIOCAD (international nonproprietary name INN: bevacizumab) as a targeted…”
Get full text

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial by Jotte, Robert, Cappuzzo, Federico, Vynnychenko, Ihor, Stroyakovskiy, Daniil, Rodríguez-Abreu, Delvys, Hussein, Maen, Soo, Ross, Conter, Henry J, Kozuki, Toshiyuki, Huang, Kuan-Chieh, Graupner, Vilma, Sun, Shawn W, Hoang, Tien, Jessop, Helen, McCleland, Mark, Ballinger, Marcus, Sandler, Alan, Socinski, Mark A

“…Cytotoxic agents have immunomodulatory effects, providing a rationale for combining atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1]) with…”
Get more information

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial by Meric-Bernstam, Funda, Makker, Vicky, Oaknin, Ana, Oh, Do-Youn, Banerjee, Susana, González-Martín, Antonio, Jung, Kyung Hae, Ługowska, Iwona, Manso, Luis, Manzano, Aránzazu, Melichar, Bohuslav, Siena, Salvatore, Stroyakovskiy, Daniil, Fielding, Anitra, Ma, Yan, Puvvada, Soham, Shire, Norah, Lee, Jung-Yun

“…Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)-directed antibody-drug conjugate approved in HER2-expressing breast and gastric…”
Get full text

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial by Ascierto, Paolo A, McArthur, Grant A, Dréno, Brigitte, Atkinson, Victoria, Liszkay, Gabrielle, Di Giacomo, Anna Maria, Mandalà, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Dutriaux, Caroline, Garbe, Claus, Yan, Yibing, Wongchenko, Matthew, Chang, Ilsung, Hsu, Jessie J, Koralek, Daniel O, Rooney, Isabelle, Ribas, Antoni, Larkin, James

“…The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously untreated patients with…”
Get full text

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial by Reck, Martin, Mok, Tony S K, Nishio, Makoto, Jotte, Robert M, Cappuzzo, Federico, Orlandi, Francisco, Stroyakovskiy, Daniil, Nogami, Naoyuki, Rodríguez-Abreu, Delvys, Moro-Sibilot, Denis, Thomas, Christian A, Barlesi, Fabrice, Finley, Gene, Lee, Anthony, Coleman, Shelley, Deng, Yu, Kowanetz, Marcin, Shankar, Geetha, Lin, Wei, Socinski, Mark A, Reck, Martin, Mok, Tony SK, Nishio, Makoto, Jotte, Robert M, Cappuzzo, Federico, Orlandi, Francisco, Stroyakovskiy, Daniil, Nogami, Naoyuki, Rodríguez-Abreu, Delvys, Moro-Sibilot, Denis, Thomas, Christian A, Barlesi, Fabrice, Finley, Gene, Lee, Anthony, Coleman, Shelley, Deng, Yu, Kowanetz, Marcin, Shankar, Geetha, Lin, Wei, Socinski, Mark A

“…The IMpower150 trial showed significant improvements in progression-free and overall survival with atezolizumab plus bevacizumab plus carboplatin plus…”
Get full text